PUBLISHER: The Business Research Company | PRODUCT CODE: 1957836
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957836
Subcutaneous immunoglobulin (SCIG) is a method of giving immunoglobulin therapy in which the medication is injected under the skin rather than into a vein. This approach allows the medication to be absorbed more slowly, lowering the risk of side effects compared to intravenous administration. SCIG is employed to manage various immune deficiencies, offering a convenient and effective way to strengthen the immune system.
The main types of subcutaneous immunoglobulin (SCIG) products include immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM). IgA is an antibody that plays a vital role in immune defense at mucosal surfaces, helping to prevent pathogens from entering the body through mucous membranes. These products are used for various applications, such as primary immunodeficiency disorders, autoimmune diseases, neurological disorders, and others, and are utilized by a range of end-users, including clinics, hospitals, homecare, and more.
Tariffs have influenced the scig market by increasing costs of plasma-derived immunoglobulins, infusion pumps, and medical-grade consumables. These impacts are most significant in regions reliant on imported plasma products and specialized delivery devices. Higher tariffs may affect treatment affordability and reimbursement dynamics. However, tariffs are encouraging plasma fractionation investments, regional manufacturing expansion, and supply chain localization.
The subcutaneous immunoglobulin (scig) market research report is one of a series of new reports from The Business Research Company that provides subcutaneous immunoglobulin (scig) market statistics, including subcutaneous immunoglobulin (scig) industry global market size, regional shares, competitors with a subcutaneous immunoglobulin (scig) market share, detailed subcutaneous immunoglobulin (scig) market segments, market trends and opportunities, and any further data you may need to thrive in the subcutaneous immunoglobulin (scig) industry. This subcutaneous immunoglobulin (scig) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The subcutaneous immunoglobulin (scig) market size has grown rapidly in recent years. It will grow from $14.39 billion in 2025 to $16.32 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to rising diagnosis of primary immunodeficiency disorders, limitations of intravenous immunoglobulin therapy, increasing need for long-term immune support, improved safety profile of scig, growing patient preference for at-home care.
The subcutaneous immunoglobulin (scig) market size is expected to see rapid growth in the next few years. It will grow to $25.71 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of scig indications beyond immunodeficiency, increasing healthcare focus on homecare therapies, technological advancements in infusion devices, growing prevalence of autoimmune and neurological disorders, rising demand for patient-centric treatment models. Major trends in the forecast period include growing shift from ivig to scig therapies, rising adoption of home-based immunoglobulin treatment, increasing preference for self-administration devices, expansion of scig use in chronic immune disorders, higher demand for long-term immune replacement therapy.
The rising prevalence of secondary immunodeficiency diseases is expected to drive the growth of the subcutaneous immunoglobulin market in the coming years. Secondary immunodeficiency diseases are conditions in which the immune system is weakened or compromised due to factors external to the immune system itself. The increase in these diseases is influenced by various factors, including aging populations, the use of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy delivers antibodies to support the weakened immune system, particularly in chronic conditions such as HIV or autoimmune disorders, thereby preventing infections and enhancing immune function during treatment. For example, in October 2024, according to HIV i-Base, a UK-based treatment activist organization, new HIV diagnoses rose by 36% among heterosexual men, increasing from 445 in 2022 to 605, and by 30% among heterosexual women, rising from 602 in 2022 to 780. Consequently, the growing prevalence of secondary immunodeficiency diseases is contributing to the expansion of the subcutaneous immunoglobulin market.
The rising prevalence of neurological disorders is anticipated to drive the growth of the subcutaneous immunoglobulin market in the coming years. A neurological disorder refers to any condition affecting the nervous system, involving anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves, including acute spinal cord injury, Alzheimer's dementia, amyotrophic lateral sclerosis (ALS), ataxia, brain tumors, and others. The increase in neurological disorders is attributed to factors such as aging populations, environmental toxins, genetic predispositions, and lifestyle changes. Subcutaneous immunoglobulin therapy can be effective in neurological disorders by supplying antibodies that regulate the immune response, reduce inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and alleviating symptoms. For example, in March 2023, the Alzheimer's Association, a US-based nonprofit voluntary health organization, reported that 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections suggesting this number could reach 13.8 million by 2060. Consequently, the growing prevalence of neurological disorders is fueling the expansion of the subcutaneous immunoglobulin market.
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are concentrating on developing innovative solutions, such as ready-to-use prefilled formulations, to improve treatment convenience, facilitate self-administration, and enhance the overall patient experience. Ready-to-use SCIG formulations are premeasured, stable immunoglobulin products intended for subcutaneous administration, enabling patients with primary immunodeficiency and other immune disorders to receive therapy more easily outside clinical environments. For example, in April 2023, the U.S. Food and Drug Administration (FDA) approved a 50 mL / 10 g prefilled syringe version of Hizentra (Immune Globulin Subcutaneous [Human] 20%), offering patients a simplified, ready-to-use option that allows more convenient home infusion and supports better treatment adherence.
Major companies operating in the subcutaneous immunoglobulin (scig) market are CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd.
North America was the largest region in the subcutaneous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (scig) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the subcutaneous immunoglobulin (scig) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The subcutaneous immunoglobulin (SCIG) market consists of revenues earned by entities by providing services such as immune system support, home-based therapy, infection prevention, personalized dosing, patient training, and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The subcutaneous immunoglobulin market also includes sales of infusion pumps, needles and catheters, syringes, and sharps disposal containers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Subcutaneous Immunoglobulin (SCIG) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses subcutaneous immunoglobulin (scig) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for subcutaneous immunoglobulin (scig) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The subcutaneous immunoglobulin (scig) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.